Vesicor Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vesicor Therapeutics is pioneering a novel drug delivery platform based on engineered cellular microvesicles (ecm) and non-viral RNA vesicles (RV) to deliver therapeutic payloads like p53 mRNA to solid tumors. Its technology aims to overcome key limitations of viral gene therapy, including immunogenicity and payload size constraints. The company is currently in the preclinical stage with its lead program, ecm-RV/p53, targeting advanced solid tumors. As a private, early-stage biotech, Vesicor's success hinges on validating its platform and advancing its first candidate into clinical trials.

Oncology

Technology Platform

A non-viral, immune-silent platform using precision-engineered cellular microvesicles (ecm) and non-viral RNA vesicles (RV) for targeted delivery of genetic payloads like mRNA directly to cancer cells.

Opportunities

The platform addresses the massive unmet need in restoring the p53 tumor suppressor, which is mutated in over 50% of cancers.

Success could also position the non-viral delivery technology as a valuable partnership asset for other genetic medicine companies facing delivery challenges.

Risk Factors

High technical risk in demonstrating effective delivery and durable biological activity in humans.

As a preclinical, private company, it faces significant financing risk and operates in a highly competitive landscape of novel drug delivery technologies.

Competitive Landscape

Vesicor competes with other non-viral delivery companies (e.g., those using lipid nanoparticles, polymers, or exosomes) and direct p53-targeting approaches. It also faces indirect competition from viral gene therapy companies and other oncology modalities like targeted therapies and immunotherapies.

More companies in Cell & Gene Therapy →More companies in United States →